VASCEPA (20 carbon hetathane) helps reduce respiratory virus infections.

Pharmaceutical company Amarin announced today that it will launch a clinical trial (THECH COVID-19 study) to study the clinical impact of ethylene 20 (VASCEPA®) in the treatment of upper respiratory tract viral infection (URI), with particular attention to adult patients with atherosclerotic cardiovascular disease (ASCVD) who are not infected with COVID-19.
COBARVID-19 study randomly assigned 1,500 patients over the age of 50 who had been diagnosed with ASCVD but did not have COVID-19, received 4 grams of 20carbon penterate (VASCEPA) per day and followed up for at least 6 months.
the main study endpoints were laboratory-confirmed rates of moderate to severe URIs (including COVID-19 and influenza), emergency care, emergency visits, or hospitalizations. the
control group will consist of 15,000 adults who meet the same eligibility criteria.
currently, ASCVD has a strong correlation with COVID-19-related morbidity and mortality, and therefore assumes that VASCEPA may play a potential role based on the factors and data associated with VASCEPA.
VASCEPA has a beneficial effect in preventing SARS-CoV-2 infection and potentially reducing the clinical severity of infected patients.
.